On January 14, 2026, at the 44th J.P. Morgan Healthcare Conference (JPM Conference), WUXI APPTEC (603259.SH, 02359) unveiled the latest progress of its GLP-1 drug pipeline. The company announced it is currently providing support for 24 different GLP-1 drugs.

According to the data disclosed by WUXI APPTEC, the company is actively developing 24 GLP-1 drug candidates, utilizing two primary technological pathways: small molecules and polypeptides. Among these, 15 candidates have already advanced to Phase II and Phase III clinical trial stages; based on the pipeline's progress, the company is poised to capture approximately 25% of the global GLP-1 related market.

The persistent shortage of GLP-1 class drugs over multiple years has potentially exposed weaknesses within the core pharmaceutical supply chain, with demand for these medications experiencing historically rare exponential growth. Some pharmaceutical enterprises, when confronted with shortages, have successfully navigated the challenges by fully mobilizing internal resources while efficiently outsourcing to select external partners, adopting flexible and continuously expanding production models.

As a key participant in the global core drug supply chain, WUXI APPTEC emphasized that its capacity expansion plans were strategically implemented well in advance. The company has recently completed the construction of a 100,000-liter solid-phase synthesis reactor, a move designed to significantly bolster its large-scale production capabilities and support the urgent needs of both partners and clinical development.

As the accessibility of GLP-1 drugs gradually increases, the treatment landscape for obesity and related metabolic diseases is expected to undergo further significant reshaping, suggesting that a veritable "therapeutic revolution" may only just be beginning.